GVR Report cover Intrathecal Pumps Market Size, Share & Trends Report

Intrathecal Pumps Market Size, Share & Trends Analysis Report By Type (Bupivacaine, Morphine), By Application (Spasticity, Pain), By Region (APAC, North America, Europe), And Segment Forecasts, 2021 - 2028

  • Published Date: Aug, 2021
  • Base Year for Estimate: 2020
  • Report ID: GVR-4-68039-508-0
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2019
  • Number of Pages: 100

Report Overview

The global intrathecal pumps market size was valued at USD 189.7 million in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 5.1% from 2021 to 2028. There is an increasing product demand owing to the rising prevalence of cancer and other chronic pain conditions. In addition, the growing geriatric population and elimination or reduced use of other pain medications are factors contributing to the market growth. Chronic pain is the major cause of disability and is linked to a high economic and social burden. For instance, according to the National Cancer Institute, the rate of new cancer cases account for 442.4 per 100,000 men and women annually. Intrathecal pumps are more beneficial than oral medications since they function directly in the CSF, allowing drugs to be absorbed more quickly and directly.

Canada intrathecal pumps market size, by type, 2018 - 2028 (USD Million)

Also, they require significantly less medication compared to oral medications. Pain pumps require around 1/300 the amount of drugs than oral medications. Advancements in technology, such as the ability of a pump to administer drugs where they are most commonly needed, increased potency, less systemic exposure, and dose required to produce the intended pharmacologic effect, are expected to propel the market growth. For Instance, Flowonix Medicals introduced a 40 mL pump, for administering the drugs into the intrathecal space; the delivery device uses a valve-gated, pressure-driven delivery mechanism and also has more than 10 years of battery life, which can help reduce the need for surgical procedures in the future.

Drug or medication delivery using an intrathecal pump helps improve comfort and relieve chronic pain, reduces the use of painkillers, allowing patients to resume their lives. Intrathecal drug delivery is used for treating the pain associated with conditions, such as unsuccessful spine and neck surgeries, chronic spine pain, neck pain, and abdominal pain. Moreover, it aids in the reduction of spasticity (muscle rigidity and spasms) and other such conditions. However, the U.S. Food and Drug Administration (FDA) has not yet approved all intrathecal pumps for usage. The FDA has issued a warning to healthcare providers and patients about the serious consequences of utilizing drugs that have not been approved by the FDA. Drugs that are licensed for intrathecal use must meet additional safety requirements. Dosing errors, infection, pump failure, opioid withdrawal, and other issues, such as muscle spasms, cognitive changes, pain, fever, vomiting, weakness, and heart or respiratory distress, are all possible risks, which may hinder the market growth.

In the elderly population, pain is a common and clinically significant condition. Unfortunately, evaluating pain in geriatric patients is challenging, mostly because of the complications of several comorbidities; however, the use of intrathecal pumps has resulted in better outcomes in the treatment of geriatric patients with pain. As a result of the growing geriatric population, the product demand is increasing. For instance, as per the WHO, the world's population of people aged 60 years and more is predicted to reach 2 billion by 2050 from 900 million in 2015.

The healthcare system has faced extraordinary challenges as a result of the COVID-19 pandemic. Due to the fact that most chronic pain services were classified as non-urgent, all elective interventional and outpatient procedures were limited or stopped during the pandemic to reduce the danger of virus transmission. However, patients with chronic pain and using an intrathecal pump who missed refill or replacement sessions faced a considerable risk and in most of the cases had to sustain by consuming oral medications, which hampered the market growth. However, with all services being resumed, the market is expected to gradually grow during the forecast period.

Type Insights

Based on type the market is segmented into baclofen, bupivacaine, clonidine, morphine, ziconotide, and others. The morphine segment accounted for the largest revenue share of over 31% in 2020. Intrathecal morphine administration is one of the most effective therapies for severe chronic pain and thus, it is usually utilized as a part of a long-term treatment plan. Opioids are regarded as the "gold standard" for the treatment of postoperative pain and with morphine being one of the most commonly used opioids in the clinical setup, it is expected to propel the segment growth.

The bupivacaine segment is expected to grow at the fastest CAGR during the forecast period. Its widespread use in postoperative pain management is contributing to its expansion. Bupivacaine administration is more effective intrathecal, providing better pain relief than epidural administration. The clonidine segment is also expected to grow at a significant rate. Intrathecal clonidine has proven to help both cancer and non-cancer pain.

Application Insights

The pain segment held the largest revenue share of more than 70% in 2020. The segment is estimated to grow at the fastest CAGR of 5.4% from 2021 to 2028. Pain is a component of many chronic illnesses, such as cancer, and chronic pain is developing as a separate health concern with severe consequences in patients. According to the School of Public Health, Boston University, chronic pain affects around 1.5 billion individuals worldwide, and the prevalence of it increases with age. As per the CDC, chronic pain affects about 50 million adults in the U.S., with high-impact chronic pain affecting around 20 million adults.

Global intrathecal pumps market share, by application, 2020 (%)

The spasticity segment is expected to grow at a CAGR of 4.6% from 2021 to 2028. Spasticity affects more than 12 million people worldwide, according to the American Association of Neurological Surgeons, with common conditions like Traumatic Brain Injury (TBI), Cerebral Palsy (CP), Spinal Cord Injury (SCI), Multiple Sclerosis (MS), and stroke accounting for the majority of the population. The market is expected to grow due to the introduction of new products by prominent manufacturers for spasticity. For example, Flowonix Medical has introduced the Prometra II Programmable Pump System, which can be used with intrathecal baclofen to treat spasticity in a variety of conditions, including multiple sclerosis.

Regional Insights

North America dominated the market and accounted for the largest revenue share of over 40.5% in 2020. The high prevalence of cancer and other related conditions, such as chronic back and neck pain, which necessitates the use of pain medications, is expected to drive market growth. For instance, as per the CDC, chronic pain affects around 50 million in the U.S. Moreover, patient outcomes & safety are of the utmost importance and various projects have been established to improve healthcare quality at an affordable cost in the U.S. North America spends far more on healthcare than any other region, which is another factor contributing to its growth.

In Asia Pacific, the market is estimated to witness the fastest CAGR of 6.9% during the forecast period. The COVID-19 pandemic has highlighted the region’s health system’s inadequacies and flaws, as well as the interdependence of health security and economic stability. As a result, the region is making progress toward its objective of obtaining Universal Health Care (UHC). Furthermore, the growing geriatric population and changing lifestyles are expected to boost the market growth in the APAC region.

Key Companies & Market Share Insights

A significant number of global and local manufacturers make the market highly competitive. To acquire a significant share of the market, major companies are implementing various growth methods, such as new product development, product differentiation approaches, financing, and international strategy. For instance, in January 2021, Flowonix Medical, a medical device company based in the U.S. that focuses on advanced, implantable drug delivery systems, has received $33 million in grants. SWK Holdings (SWKH), a specialist finance company that works with small- and mid-sized commercial-stage life-science companies, provided a $10 million debt facility as part of the transaction. The following are some of the major participants in the global intrathecal pumps market:

  • Tricumed Medizintechnik GmbH

  • Codman and Shurtleff

  • Teleflex, Inc.

  • Flowonix Medical, Inc.

  • Zimmer Biomet

  • Medtronic

Intrathecal Pumps Market Report Scope

Report Attribute


Market size value in 2021

USD 325.6 Million

Revenue forecast in 2028

USD 462.1 Million

Growth rate

CAGR of 5.1% from 2021 to 2028

Base year for estimation


Historical data

2016 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Type, application, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K., Germany; France; Italy; Spain; Japan; China; India; Thailand; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE

Key companies profiled

Tricumed Medizintechnik GmbH; Codman and Shurtleff; Teleflex, Inc.; Flowonix Medical, Inc.; Zimmer Biomet; Medtronic

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global intrathecal pumps market report on the basis of type, application, and region:

  • Type Outlook (Revenue, USD Million, 2016 - 2028)

    • Baclofen

    • Bupivacaine

    • Clonidine

    • Morphine

    • Ziconotide

    • Others

  • Application Outlook (Revenue, USD Million, 2016 - 2028)

    • Spasticity

    • Pain

  • Regional Outlook (Revenue, USD Million, 2016 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Italy

      • Spain

    • Asia Pacific

      • Japan

      • China

      • India

      • Thailand

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East and Africa

      • South Africa

      • Saudi Arabia

      • UAE

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.